- Table of Contents
We validate the specificity of these antibodies to TNFSF18 by testing them on tissues known to express TNFSF18 positively and negatively. Browse below to find the TNFSF18 antibody that suites your experiment. We have 6 of these antibodies and many publications and validation images.
If you cannot find antibodies that fit your needs, contact us for making custom antibodies. We have a full suite of custom antibody services covering from research to diagnostic and therapeutic applications.
Facts about Tumor necrosis factor ligand superfamily member 18.
Important for interactions between activated T-lymphocytes and endothelial cells. Mediates activation of NF-kappa-B.
|tumor necrosis factor family|
Activation-inducible TNF-related ligand; AITRL; AITRLMGC138237; GITR Ligand; GITRL; GITRLglucocorticoid-induced TNFR-related protein ligand; Glucocorticoid-induced TNF-related ligand; hGITRLGITR ligand; TL6AITR ligand; TNFSF18; tumor necrosis factor (ligand) superfamily, member 18; tumor necrosis factor ligand superfamily member 18
|Sequence:||1; NC_000001.11 (173041220..173050963, complement)|
Expressed at high levels in the small intestine, ovary, testis, kidney and endothelial cells.
Cell membrane; Single-pass type II membrane protein.
High-affinity primary antibodies and TNFSF18 are the three most important components of Boster Bio's TNFSF18 Marker. These primary antibodies have many different applications in biology, medicine, and veterinary medicine. The high-affinity antibodies can be used to measure TNFSF18 in specific species and to investigate the effects of certain treatments on these creatures. Scientists can also submit their results and receive product credits. These credits are offered to all scientists worldwide.
TNFSF18 is a member of the tumor necrosis factor family and is expressed in the small intestine and in endothelial cells. It plays a role in immune response by mediating interactions between activated T-lymphocytes and other cell types. Inflammatory reactions in the body are triggered by TNFSF. It is also associated with the inflammatory response and is expressed by various cell types, including NK cells, T cells, and B lymphocytes.
Antibodies against TNFSF18 are available in a variety of species, including mouse and human. The clinical benchmark antibody is raised against purified human GITR and blocks GITR's natural ligand. It is suitable for in vitro experiments and can be used for diagnosis and research. These antibodies are not suitable for human use. They are guaranteed for one year from the date of purchase.
However, high antibody affinity is not always desirable as it can make elution from the affinity column difficult. This may require denaturing or harsher methods. If this is not possible, use polymeric Fab forms of the secondary antibodies. This way, you can prevent passive capture of the primary antibody by the secondary antibodies. Further, high-affinity primary antibodies against the TNFSF18 marker will not cross-react with the TNFSF18 marker.
B cells have been implicated in regulating Treg proliferation. The TFH transcriptional programs control the class-specific evolution of high-affinity B cells. These cells regulate antigen recall. Using the TFH-/ mouse model, the number of Tregs in these mice was significantly reduced. This suggests that the TFH population mediates the regulation of antigen recall.
Moreover, high-affinity primary antibodies against the TNF-SF18 marker are effective tools for analyzing the effects of TNFSF in tumors. These antibodies have the potential to reduce the symptoms of cancer by blocking TNFSF expression. The TNFSF-18-antibody is effective in the detection of multiple cancers, including those induced by inflammatory processes. The GITR antigen, a marker of TNFSF18, is a widely-used antigen.
Biological assays often use antibodies to detect TNFSF18. These antibodies can be monoclonal or polyclonal, and can react with TNFSF18 from a variety of animal samples. Boster Bio uses rabbit and mouse as models for developing TNFSF18 antibodies. This receptor regulates T-cell responses and is a costimulator, which lowers the threshold for T-cell proliferation. It also regulates NF-kappa-B signaling in immune cells.
The TNFSF18 gene is a part of a family of proteins called TNFRSF, which are expressed by several immune cells, including T cells. This marker provides biomarkers for the immune system. It is thought that the expression of TNFSF18 in various types of cancer is beneficial for various types of immunotherapy. This protein is expressed by different populations of immune cells including T cells, and is used in various clinical applications.
The HERA-GITRL antibody, a hexavalent human GITR agonist, has a higher ability to induce T cell signaling in cancer patients than that of the trivalent GITRL. However, the clinical benchmark antibody, anti-GITR, significantly reduced the anti-tumor immune response. The antibody is a potential immunosuppressive agent and can be associated with a variety of side effects.